Scienza e Tecnologia
Cambridge Isotope Laboratories, Inc. Announces (13)C Cascade Production Optimization at Ohio Plant
"As we work to increase our operations and capabilities for our customers we sometimes need to think creatively for better solutions. This project is an example of using different problem-solving methods to achieve a better operating production cascade," says Mike Steiger , VP of Project Engineering and Execution.
CIL's isotope-separation facility houses the world's largest C and one of the world's largest 18O isotope-separation facilities. This facility also has the world's only commercial D2O enrichment columns. These factors allow CIL to continue to be the world's leading producer of stable isotopes and stable isotope-labeled compounds for analytical and research applications. Having process control of stable isotope starting materials ensures inventory of needed synthetic precursors and allows tight control over the product quality demanded by CIL.
CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the
Boston, MA , area; a large isotope-enrichment production plant in
Xenia, OH ; CIL China; CIL Canada; ABX in
Dresden , Germany ; and Eurisotop in Saclay,
France .
For more information on CIL, visit .
cambridge-isotope-laboratories-inc.jpg
Photo - https://mma.prnewswire.com/media/1386201/Cambridge_Isotope_Laboratories.jpg